CSPC's DP303c (enweiqutuozhumab): A commercialization test of "beating the comparator, only to face a stronger rival"

To understand DP303c, first understand its owner. CSPC is one of the Chinese pharma companies with the highest finished-drug revenue, with a professional sales force of over 10,000 covering medical institutions at every level nationwide. Its oncology business rests on chemotherapy and supportive care: paclitaxel for injection (albumin-bound) "Keaili", doxorubicin hydrochloride liposome "Duomeisu" and PEGylated recombinant human G-CSF "Jinyouli" form a mature in-hospital oncology sales and access network. In other words, CSPC's "door-opening ability" in oncology departments is strong, but it has never had a specialty medical team built around HER2 and targeted breast cancer therapy — a point that will recur below.

DP303c was developed by CSPC's Megalith Biopharmaceutical. It is a recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate. Its engineering highlight is site-specific enzymatic conjugation: the drug-to-antibody ratio (DAR) is stable at 2.0 with high homogeneity and a cleavable linker, making it a so-called third-generation site-specific ADC. In preclinical models it showed antitumor activity comparable or superior to T-DM1. It is the first in-house molecule on CSPC's ADC map, and a cornerstone of the company's transition from "chemical pharma + generic-innovation" to "biologics + ADC platform".

DP303c's payload is MMAE (a microtubule inhibitor) and its DAR is only 2.0; whereas the most closely watched group of HER2 ADCs today — T-DXd, Hengrui's SHR-A1811 and DualityBio's DB-1303 — use topoisomerase I inhibitor payloads with higher DAR, a stronger bystander effect, and established data in HER2-low populations. Site-specific conjugation improves DP303c's homogeneity, but it is indeed weaker than this group in bystander effect and HER2-low coverage.

A special caution, however: an ADC cannot be written off simply because "its DAR is low and its payload is a microtubule agent". Another domestic HER2 ADC that also uses a low DAR and a microtubule inhibitor payload — Kelun-Biotech's A166 (trastuzumab botidotin, Shutailai®) — achieved mPFS of 11.1 vs 4.4 months, HR 0.39 in a head-to-head Phase 3 against T-DM1, and was approved in China in October 2025. This shows that ADC efficacy is determined jointly by antibody, linker, payload, DAR, internalization and release; looking only at payload class leads to misjudgment. DP303c's real problem is not the a priori conclusion that "its payload is outdated", but two more specific things discussed below: its own efficacy numbers are modest within its class, and it is entering too late.

First, what it got right. DP303c's Phase 3 did not take the shortcut of a single-arm accelerated path but chose a randomized, open-label, head-to-head design, with the primary endpoint assessed blind by an independent imaging committee — the level of evidence is itself solid. 448 patients, HR 0.56, p<0.0001, and investigator-assessed PFS (9.7 vs 6.9 months) consistent in direction with the BICR result. ORR of 62.8% vs 42.8% and clinical benefit rate of 68.6% vs 50.9% both point to a real efficacy advantage. On safety, permanent discontinuation due to adverse events was only 0.9% (1.4% in the control arm), and only one case of ulcerative keratitis was reported in Phase 3, with no corneal perforation or blindness. It is a neat report card.

But neat does not mean leading. The problem lies in the question the control arm answers. The formal start date of this Phase 3 (NCT06313086) was March 2024 — while T-DXd had already been approved in China for second-line HER2-positive breast cancer back in February 2023. In other words, this head-to-head design was not a case of "T-DXd didn't exist yet when the study was planned"; T-DM1 was chosen as the comparator after T-DXd had already become the new second-line standard. T-DM1 remains an effective and regulatorily acceptable active comparator, and choosing it raises no compliance issue; but the price is that the study did not directly answer the question clinicians most want answered: "what is DP303c worth relative to T-DXd, the then-new second-line standard?"

Three HER2 ADC Phase 3 trials, all with T-DM1 as comparator (different studies; absolute numbers cannot be directly subtracted)

The three studies differ in population, follow-up and cutoffs, so absolute numbers cannot be directly subtracted. But the most meaningful reference is A166 — like DP303c it has a low DAR and a microtubule inhibitor payload, also used T-DM1 as comparator, and was also studied in patients after trastuzumab + taxane, making it a more direct comparison than a cross-trial one with T-DXd. In this closest domestic comparison, DP303c's mPFS (8.8) and HR (0.56) are both inferior to A166's (11.1; 0.39), and so is its ORR (62.8% vs about 77% for A166).

Two limitations must also be honestly pointed out. First, follow-up is extremely short: median follow-up for the SABCS data was only 7.4 months, and overall survival (OS) is far from mature. Whether the 8.8-month PFS advantage translates into durable benefit and delivers on OS remains an open question. Second, ocular toxicity is an issue this class of microtubule-payload ADCs must confront. In DP303c's Phase 1 data, any-grade ocular adverse events reached 94.7%, including 21.3% grade 3, keratopathy 87.2% and blurred vision 61.7%; the dose-limiting toxicity was precisely grade 3 eye pain at 4.0 mg/kg. The Phase 3 abstract only disclosed "just one case of ulcerative keratitis, no corneal perforation or blindness", but did not publish the overall incidence and grading of any-grade ocular events — so one cannot conclude from this that ocular toxicity has been substantially reduced; it remains an open issue (the Phase 3 of its peer A166 also singled out ocular toxicity management as a point of attention).

On interstitial lung disease (ILD), a common misreading needs correcting: DP303c is not "free of ILD risk". Its Phase 1 study actually observed 4 cases of ILD (4.3%), all grade 1; the Phase 3 abstract did not publish the full ILD incidence. So for now one can only say: in early studies ILD cases were few and low-grade, with no high-grade events reported — but this cannot be equated with "no ILD". Benchmarking against T-DXd on "no pulmonary toxicity", or differentiating by "trading ocular toxicity for pulmonary toxicity", does not hold, and that narrative should be abandoned. Evidence for DP303c's safety differentiation versus T-DXd is currently insufficient.

Compared with its two weak spots of relative efficacy and competition, China registration is a relatively smooth stretch for DP303c. As a Class 1 innovative drug on a purely Chinese development path, it carries no ethnic bridging burden; HER2 testing (IHC/ISH) in China is a nationally standardized program with full coverage in tertiary hospitals, mature reimbursement and fast turnaround — the least worrying link for any HER2 ADC. Chinese patient exposure is also sizable: 94 in Phase 1 and 226 in Phase 3, plus an ovarian cancer Phase 2. But to be clear: acceptance does not mean the regulator has deemed the evidence sufficient. The safety database is large enough in "quantity", but that does not mean its content (especially complete ocular and ILD incidence) has been endorsed by reviewers; that still awaits the review conclusion.

What can be confirmed is that DP303c's marketing application was accepted by CDE on July 16, 2026, acceptance no. CXSS2600105. In addition, HER2 ADCs such as T-DXd, Hengrui's SHR-A1811 and Kelun-Biotech's A166 have been approved in China, so review precedents are clear. But to date, there has been no formal notice of DP303c being granted priority review, nor any public basis for claiming it "meets priority review / conditional approval criteria" — such judgments should be avoided. Any specific approval timing (possibly 2027 at the earliest) is only an estimate, subject to the final review outcome.

Relatively smooth registration only highlights the commercial awkwardness: the target label lands in an already very crowded position. DP303c is going for the label "second-line HER2-positive, after trastuzumab + taxane" — here there is not only T-DXd (approved 2023, NRDL 2025), but also A166 (approved October 2025) and SHR-A1811 (approved for HER2+ breast cancer in March 2026). Registration can get the license, but what it gets is a ticket into a red ocean.

For a large pharma like CSPC, whether an ADC without an absolute efficacy advantage can make money often depends not on the molecule itself but on the amplifying power of the commercial platform. That is where DP303c's real value battle lies.

How long is CSPC's commercial lever? A sales force of over 10,000, a mature in-hospital oncology access network, and the relationships and channels built in oncology departments by Keaili, Duomeisu and Jinyouli mean that once DP303c is approved, it can rapidly reach tertiary breast centers nationwide through existing teams and networks. This is a level of execution biotechs cannot match, and the core of the "commercial platform leverage" logic.

But this lever has a soft fulcrum. CSPC's oncology base is chemotherapy and supportive care, not HER2-targeted therapy. It has no specialty medical team that has spent years cultivating HER2/breast cancer like Roche or Hengrui, and it lacks academic assets with long-term ties to breast cancer KOLs. To convince clinicians in a market where T-DXd has already completed physician education — "why use DP303c rather than T-DXd?" — CSPC needs to build this HER2 specialty messaging from scratch: plenty of "door-opening ability", but "specialty persuasiveness" still to be built.

So how to play differentiation? First, an uncomfortable fact must be acknowledged: DP303c currently has no proven differentiating advantage. On efficacy it trails its peers A166 and T-DXd; on safety, "no ILD" does not hold (4.3% grade 1 ILD in Phase 1), and full ocular toxicity data have not been disclosed. So in reality the playable cards are mainly one card it has to substantiate itself, plus one direction still to be validated:

Stacking these on a 10,000-person platform, DP303c's more realistic positioning is not "second-line first choice", but "a cheaper domestic HER2 ADC option rolled out efficiently by a 10,000-strong team". This sets the ceiling of its China sales curve: it will not be a blockbuster, and facing domestic rivals such as A166 and SHR-A1811 that were approved first, building a solid mid-sized product through platform-driven volume plus a price narrative is possible, but by no means easy.

China has about 350,000–400,000 new breast cancer cases a year, about 20% of them HER2-positive, i.e. 70,000–80,000 per year. The second-line population base is substantial — but this pond is packed with rivals. Describing the crowding of the domestic same-target ecosystem as "full bars" is no exaggeration:

This table makes DP303c's situation clear. It is not the front-runner in the domestic HER2 ADC breast cancer race, but a latecomer: before it received its acceptance number, the HER2+ breast cancer indication in China already had two imported originators, T-DM1 and T-DXd, plus two domestic approvals, A166 (2025-10) and SHR-A1811 (2026-03). That is, if DP303c is approved, it will be at least the 5th HER2+ breast cancer ADC approved in China and the 3rd domestic one.

More awkward still is the closest domestic comparator, A166: also low-DAR with a microtubule inhibitor payload, also using T-DM1 as comparator, yet it produced better PFS and HR, and was approved almost a year earlier. This both refutes the simplistic attribution that "DP303c's weaker efficacy is because its payload is a generation behind" (A166, of the same class and generation, is stronger), and puts DP303c in an even more uncomfortable position — it is not even "the better one among domestic peers".

Moving up to earlier lines is not easy either. In theory DP303c could go into first line or the perioperative setting, but that is where T-DXd's DESTINY-Breast09/05 series is taking ground; HER2-low is currently mainly held by topoisomerase I payload ADCs with established data, and DP303c has not yet produced efficacy evidence in HER2-low, so this slice of the pie is not its in the short term — but this is "not yet proven able to enter", not "destined never to enter", and depends on future data.

Fortunately, the PI network at leading breast centers is friendly to CSPC: the Phase 1 study was led by Professor Hu Xichun of Fudan University Shanghai Cancer Center, and a breast cancer clinical network of leading experts including Xu Binghe, Jiang Zefei, Shao Zhimin, Ma Fei and Wang Shusen is already in place, leaving a channel for later medical promotion and real-world studies.

At the CMC level, DP303c is broadly "controllable domestically, unproven globally". CSPC Megalith has a biologics/ADC manufacturing system; while site-specific enzymatic conjugation has some complexity, the company already has ADC platform experience, and commercial capacity and the local release chain are essentially complete. It should be noted that claims such as "manufacturing cost significantly lower than peers" or "almost no reliance on CDMOs" are currently not supported by public cost or capacity data and can only be treated as speculation — basing DP303c's price card on the market experience that "domestic originators are usually cheaper than imports" is safer than basing it on an unproven COGS advantage.

But once going abroad comes up, the weaknesses show. Global GMP inspection records for ADCs facing FDA/EMA have not been sufficiently validated, and the quality and compliance systems needed for overseas registration are still being built. Combined with DP303c's global value dilemma (next section), this essentially rules it out as a "globally self-commercialized" product in the near term.

This is the key section for understanding DP303c's fate. CSPC has been extremely active in ADCs and out-licensing over the past two years: its EGFR ADC (SYS6010) won two breakthrough designations within six months, plus a ROR1 ADC and a Nectin-4 ADC (SYS6002), along with a string of out-licensing deals (lipoprotein(a), MAT2A inhibitor, irinotecan liposome, etc.). The company clearly treats "next-generation ADC platform + large out-licensing deals" as the main thread of its global narrative.

On this board, DP303c looks more like a piece for "China commercial realization" than for "global R&D charge". As CSPC's first in-house ADC it has foundational significance; but given its current efficacy position (behind peers A166 and T-DXd) and global competitiveness, its global R&D priority is likely to yield to newer-generation molecules. Fortunately CSPC's other ADCs hit different targets (EGFR/ROR1/Nectin-4), so there is no same-target cannibalization with DP303c; the conflict is mainly over allocation of R&D resources and commercial attention.

There is another structural positive: CSPC is not short of money. Ample cash and not being financing-driven mean DP303c is not constrained by runway; even if review is delayed or sales ramp slowly, the company can absorb it. This lets it calmly position DP303c in a dual role of "solid mid-sized product + platform training ground", without being forced to sell global rights cheaply under unfavorable conditions.

DP303c is an easily misread asset. Its Phase 3 headline — beating T-DM1 head-to-head, HR 0.56, marketing application accepted — reads like a victory story; but put back on the real battlefield of 2026, it looks more like a commercialization test of "right direction, late entry, and not the strongest in its class". Its efficacy does justice to the T-DM1 comparator, but falls short both of the global benchmark T-DXd and of A166, a domestic peer approved earlier; its registration is relatively smooth, but plunges into the heart of a red ocean with at least four approved HER2 ADCs; its owner has a 10,000-person platform, but lacks a HER2 specialty gun.

That does not mean it has no value. For CSPC, DP303c matters in two ways: it is the first cornerstone of the in-house ADC platform, and a realistic asset that can become a solid mid-sized product through accessibility and safety differentiation and platform-driven volume. The key is to give it an honest positioning — not to be king of the second line, but to be the domestic option that is "cheaper, better suited to specific populations, and rolled out efficiently by a 10,000-strong team". Anchor valuation expectations, resource investment and the overseas narrative to this real positioning, and DP303c can turn from "a me-too in T-DXd's shadow" into a precisely deployed piece on the board.